We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.79 | -1.03% | 75.56 | 75.61 | 75.65 | 30,846 | 12:28:17 |
From May 2021 to May 2024
By Anthony O. Goriainoff
AstraZeneca PLC said Tuesday that its Lynparza drug's supplemental new drug application has been accepted and granted Priority Review by the U.S. Food and Drug Administration.
Lynparza is used for the treatment of patients with early breast cancer who have already been treated with chemotherapy either before or after surgery, the London-listed company said.
The Anglo-Swedish pharmaceutical company said the application was based on results from the OlympiA phase 3 trial which showed Lynparza demonstrated a statistically significant improvement in invasive disease-free survival.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
November 30, 2021 02:34 ET (07:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
